CTC Pancreatic Adenocarcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02335151|
Recruitment Status : Completed
First Posted : January 9, 2015
Last Update Posted : December 13, 2019
|Condition or disease||Intervention/treatment||Phase|
|Adenocarcinoma Circulating Tumor Cells Pancreatic Neoplasms||Drug: Desflurane||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||86 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells?|
|Actual Study Start Date :||October 2016|
|Actual Primary Completion Date :||September 2019|
|Actual Study Completion Date :||October 2019|
General anesthesia with Desflurane
Apply desflurane as anesthetic
Other Name: Suprane
No Intervention: Propofol
General anesthesia with Propofol
- Peak of CTC in the postoperative phase after curative tumor removal [ Time Frame: Day 0 to Day 7 ]CTC will be counted and peak of CTC will be determined.
- Kinetics of CTC after surgery up to day 7 [ Time Frame: 1 year ]CTC will be counted and kinetics of CTC will be determined.
- Month to Tumor recurrence [ Time Frame: 1 year ]Tumor recurrence will be monitored.
- Number of surviving patients [ Time Frame: 1 year ]One year after surgery the number of patients still being alive will be determined.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02335151
|Kantonsspital St. Gallen|
|St. Gallen, Switzerland, 9007|
|Winterthur, Switzerland, 8401|
|University Hospital Zurich|
|Zurich, Switzerland, 8091|
|Zürich, Switzerland, 8063|
|Principal Investigator:||Beatrice Beck Schimmer, Prof. MD||University of Zurich|